Tardive Dyskinesia Clinical Trial
Official title:
The Assessment of Movement Disorders Utilizing Live Two-Way Video
Verified date | September 2016 |
Source | Northwell Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this project is to determine the equivalency of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) examinations conducted via live two-way video versus live examinations completed in-person
Status | Completed |
Enrollment | 37 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and - That have been compliant for the past week. Exclusion Criteria: - Patients who have medical conditions which make it difficult to perform a physical examination. - Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures. |
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
United States | The Zucker Hillside Hospital | Glen Oaks | New York |
Lead Sponsor | Collaborator |
---|---|
Northwell Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Abnormal Involuntary Movement Scale (AIMS) when done in-person versus via two-way video | Baseline | No | |
Primary | Modified Simpson Angus Scale (mSAS) short version when done in-person versus via two-way video | Baseline | No | |
Secondary | the correlation between the short version and full version of the Modified Simpson Angus Scale (mSAS) | total score of short version-Modified Simpson Angus Scale vs. total score of full version-Modified Simpson Angus Scale | Baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02840760 -
Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
|
N/A | |
Completed |
NCT01688037 -
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
|
Phase 2 | |
Completed |
NCT01391390 -
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
|
N/A | |
Withdrawn |
NCT03254186 -
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Completed |
NCT02291861 -
Addressing Involuntary Movements in Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT02274558 -
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT02198794 -
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT04794413 -
Pimavanserin Treatment in TS
|
Early Phase 1 | |
Recruiting |
NCT06011408 -
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
|
N/A | |
Recruiting |
NCT05859698 -
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
|
Phase 4 | |
Active, not recruiting |
NCT02252380 -
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
|
N/A | |
Terminated |
NCT00917293 -
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
|
Phase 2 | |
Completed |
NCT01543321 -
Xenazine in Late Dyskinetic Syndrome With Neuroleptics
|
Phase 3 | |
Completed |
NCT02405091 -
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT03176771 -
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Terminated |
NCT02524886 -
Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
|
N/A | |
Completed |
NCT02195700 -
Aim to Reduce Movements in Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Completed |
NCT02736955 -
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT03497013 -
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
|
N/A | |
Withdrawn |
NCT01908452 -
Pyridoxal Kinase Activity in Tardive Dyskinesia
|
Phase 3 |